201 related articles for article (PubMed ID: 22262072)
1. SGLT-2 inhibitors in development for type 2 diabetes treatment.
Bhartia M; Tahrani AA; Barnett AH
Rev Diabet Stud; 2011; 8(3):348-54. PubMed ID: 22262072
[TBL] [Abstract][Full Text] [Related]
2. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
4. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
6. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
8. [Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
Rosak C; Forst T
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():95-101. PubMed ID: 23326927
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Nathan KT; Ahmed-Sarwar N; Werner P
Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654
[TBL] [Abstract][Full Text] [Related]
10. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Miller K; Miller EM
J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin for the treatment of type 2 diabetes.
Brooks AM; Thacker SM
Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
15. [SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Nauck M; Del Prato S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S4-5. PubMed ID: 23529569
[No Abstract] [Full Text] [Related]
16. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
17. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Gerich JE; Bastien A
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852
[TBL] [Abstract][Full Text] [Related]
18. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Mende CW
Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
[TBL] [Abstract][Full Text] [Related]
20. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
